Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

(2020) Calvin J. Gordon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

(2020) Yeming Wang et al.   LANCET

Remdesivir for the Treatment of Covid-19 — Preliminary Report

(2020) John H. Beigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatic disorders with the use of remdesivir for coronavirus 2019 (COVID-19)

(2020) François Montastruc et al.   Clinical Gastroenterology and Hepatology

Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy

(2020) Sweilem B. Al Rihani et al.   Journal of Clinical Medicine

Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre‐COVID‐19 reports

(2020) Adam Goldman et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

(2019) Sabue Mulangu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessment of the clinical cardiac drug-drug interaction associated with the combination of hepatitis C virus nucleotide inhibitors and amiodarone in guinea pigs and rhesus monkeys

(2016) Christopher P. Regan et al.   HEPATOLOGY

Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C

(2015) Tariq Ahmad et al.   HEPATOLOGY

Bradyarrhythmias Associated with Sofosbuvir Treatment

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Finding Meaningful Patterns in Adverse Drug Event Reports

(2014) Joshua J. Gagne   JAMA Internal Medicine

Postmarketing Safety Surveillance

(2013) Preciosa M. Coloma et al.   DRUG SAFETY

The Mechanism of the Negative Chronotropic and Dromotropic Actions of Adenosine 5ʼ-triphosphate in the Heart: An Update

(2010) Amir Pelleg et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY